At the 2025 ESMO Asia Congress, Professor George K.K. Lau, Chairman of Humanity & Health Medical Group, Hong Kong, presented for the first time data from a Chinese population study on Tremelimumab combined with durvalumab in patients with unresectable hepatocellular carcinoma. The study closely reflects the disease characteristics and epidemiological profile of Chinese patients, providing targeted, high quality evidence based support for liver cancer treatment in China. It has positive implications for optimizing and advancing precision approaches in liver cancer diagnosis and management.
